0001564590-21-053942 | 10-Q | XBRL Viewer

Label	Element	Value
Accrued External Clinical Study Costs	gthx_AccruedExternalClinicalStudyCosts	$ 8,992,000
Accrued External Clinical Study Costs	gthx_AccruedExternalClinicalStudyCosts	5,683,000
Line Of Credit Facility Upfront Fee	gthx_LineOfCreditFacilityUpfrontFee	200,000
Line Of Credit Facility Upfront Fee	gthx_LineOfCreditFacilityUpfrontFee	100,000
Maximum Milestone Payments	gthx_MaximumMilestonePayments	156,000,000.0
Maximum Milestone Payments	gthx_MaximumMilestonePayments	8,000,000.0
Maximum Milestone Payments	gthx_MaximumMilestonePayments	330,000,000.0
Maximum Gross Proceeds Of Common Stock Allowed From Issuance And Sell	gthx_MaximumGrossProceedsOfCommonStockAllowedFromIssuanceAndSell	125,000,000.0
Maximum Gross Proceeds Of Common Stock Allowed From Issuance And Sell	gthx_MaximumGrossProceedsOfCommonStockAllowedFromIssuanceAndSell	150,000,000.0
Upfront Cash Payment Receivable Under Agreement	gthx_UpfrontCashPaymentReceivableUnderAgreement	$ 6,000,000.0
Senior Advisor Agreement Expiration Date	gthx_SeniorAdvisorAgreementExpirationDate	Dec. 31, 2023
Non Cash Interest Expense	gthx_NonCashInterestExpense	$ 236,000
Non Cash Interest Expense	gthx_NonCashInterestExpense	161,000
Upfront Cash Payment Received	gthx_UpfrontCashPaymentReceived	20,000,000.0
Upfront Cash Payment Received	gthx_UpfrontCashPaymentReceived	14,000,000.0
Upfront Cash Payment Received	gthx_UpfrontCashPaymentReceived	14,000,000.0
Other Income Expense	gthx_OtherIncomeExpense	(76,000)
Other Income Expense	gthx_OtherIncomeExpense	(291,000)
Other Income Expense	gthx_OtherIncomeExpense	(208,000)
Other Income Expense	gthx_OtherIncomeExpense	$ (488,000)
At The Market Public Offering Shares Issued	gthx_AtTheMarketPublicOfferingSharesIssued	3,513,027
Proceeds From Stock Options And Warrants Exercised	gthx_ProceedsFromStockOptionsAndWarrantsExercised	$ 5,828,000
Proceeds From Stock Options And Warrants Exercised	gthx_ProceedsFromStockOptionsAndWarrantsExercised	1,836,000
Accrued Professional Fees And Other Current	gthx_AccruedProfessionalFeesAndOtherCurrent	7,337,000
Accrued Professional Fees And Other Current	gthx_AccruedProfessionalFeesAndOtherCurrent	3,920,000
Increase In Net Carrying Amount Of Loan	gthx_IncreaseInNetCarryingAmountOfLoan	9,800,000
Proceeds From Loan Agreement	gthx_ProceedsFromLoanAgreement	10,000,000
Proceeds From Loan Agreement	gthx_ProceedsFromLoanAgreement	$ 20,000,000
Number Of Days Due From Invoice Date	gthx_NumberOfDaysDueFromInvoiceDate	30 days
Non Cash Equity Interest Net	gthx_NonCashEquityInterestNet	$ 228,000
Non Cash Equity Interest Net	gthx_NonCashEquityInterestNet	(926,000)
At The Market Public Offering Value Of Shares Issued	gthx_AtTheMarketPublicOfferingValueOfSharesIssued	86,378,000
At The Market Public Offering Value Of Shares Issued	gthx_AtTheMarketPublicOfferingValueOfSharesIssued	86,378,000
Potential Milestone Payments Receivable	gthx_PotentialMilestonePaymentsReceivable	40,000,000.0
Potential Milestone Payments Receivable	gthx_PotentialMilestonePaymentsReceivable	290,000,000.0
Potential Milestone Payments Receivable	gthx_PotentialMilestonePaymentsReceivable	$ 156,000,000.0
Period For Payment On Invoice Terms	gthx_PeriodForPaymentOnInvoiceTerms	30 days
Upfront Payments Receivable And Sales Based Royalties	gthx_UpfrontPaymentsReceivableAndSalesBasedRoyalties	$ 14,000,000.0
Upfront Payments Receivable And Sales Based Royalties	gthx_UpfrontPaymentsReceivableAndSalesBasedRoyalties	26,000,000.0
Other Nonoperating Interest Income	gthx_OtherNonoperatingInterestIncome	7,000
Other Nonoperating Interest Income	gthx_OtherNonoperatingInterestIncome	50,000
Other Nonoperating Interest Income	gthx_OtherNonoperatingInterestIncome	35,000
Other Nonoperating Interest Income	gthx_OtherNonoperatingInterestIncome	$ 922,000
Prepayment Fee Description	gthx_PrepaymentFeeDescription	(a) 3.0% of the prepayment amount in the first year; (b) 2.0% of the prepayment amount in the second year; and (c) 1.0% of the prepayment amount in the third year.
Withholding Taxes	gthx_WithholdingTaxes	$ 1,400,000
Withholding Taxes	gthx_WithholdingTaxes	800,000
Upfront Project Costs And Other Current Assets In Accounts Payable And Accrued Expenses	gthx_UpfrontProjectCostsAndOtherCurrentAssetsInAccountsPayableAndAccruedExpenses	114,000
Accrued External Research	gthx_AccruedExternalResearch	2,205,000
Accrued External Research	gthx_AccruedExternalResearch	3,219,000
Other Nonoperating Interest Expense	gthx_OtherNonoperatingInterestExpense	934,000
Other Nonoperating Interest Expense	gthx_OtherNonoperatingInterestExpense	757,000
Other Nonoperating Interest Expense	gthx_OtherNonoperatingInterestExpense	2,609,000
Other Nonoperating Interest Expense	gthx_OtherNonoperatingInterestExpense	1,022,000
Debt Instrument End Of Term Fee Amount	gthx_DebtInstrumentEndOfTermFeeAmount	2,100,000
Fair Value Measurement Amount Of Changes In Valuation Methodology	gthx_FairValueMeasurementAmountOfChangesInValuationMethodology	0
Fair Value Measurement Amount Of Changes In Valuation Methodology	gthx_FairValueMeasurementAmountOfChangesInValuationMethodology	0
Fair Value Measurement Amount Of Changes In Valuation Methodology	gthx_FairValueMeasurementAmountOfChangesInValuationMethodology	$ 0
Consulting Agreements Expiration Date	gthx_ConsultingAgreementsExpirationDate	Jun. 30, 2021
Consulting Agreements Expiration Date	gthx_ConsultingAgreementsExpirationDate	Jun. 30, 2022

Patent License Agreement - Additional Information (Details) - USD ($)		9 Months Ended	58 Months Ended
	May 29, 2020	Sep. 30, 2021	Sep. 30, 2021
Patent License Agreement [Line Items]
License agreement date		Nov. 23, 2016
License agreement amendment date		Mar. 24, 2017
Milestone payments	$ 20,000,000.0	$ 2,600,000	$ 600,000
Term of license agreement description		The term of the license agreement will continue until the later of (i) the expiration of the last valid claim within the patent rights covering the product in such country, (ii) the expiration of market exclusivity in such country and (iii) the 10th anniversary of the first commercial sale in such country. The University may terminate the agreement in the event (i) the Company fails to pay any amount or make any report when required to be made and fails to cure such failure within thirty (30) days after receipt of notice from the University, (ii) is in breach of any provision of the agreement and fails to remedy within forty-five (45) days after receipt of notice, (iii) makes a report to the University under the agreement that is determined to be materially false, (iv) declares insolvency or bankruptcy or (v) takes an action that causes patent rights or technical information to be subject to lien or encumbrance and fails to remedy any such breach within forty-five (45) days of receipt of notice from the University. The Company may terminate the agreement at any time on written notice to the University at least ninety (90) days prior to the termination date specified in the notice. Upon expiration or termination of the agreement, all rights revert to the University.
License agreement termination notice period		90 days

Print Document View Excel Document
Notes Details Patent License Agreement - Additional Information (Details) Uncategorized Uncategorized Items - gthx-10q_20210930_htm.xml All Reports